KYSE-150 Xenograft Model Service for Esophageal Squamous Cell Carcinoma (ESCC)

KYSE-150 Xenograft Model Service for Esophageal Squamous Cell Carcinoma (ESCC) provides a robust preclinical platform for evaluating therapeutic efficacy against one of the most aggressive upper gastrointestinal malignancies. Alfa Cytology delivers fully validated, high-fidelity KYSE-150 xenograft models with comprehensive pharmacodynamic and tumor growth monitoring endpoints to accelerate your ESCC drug development pipeline.

Overview of KYSE-150 Xenograft Model for Esophageal Squamous Cell Carcinoma (ESCC)

The KYSE-150 cell line was established from a primary esophageal squamous cell carcinoma resected from a 49-year-old female patient of Asian ethnicity. As part of the extensively characterized KYSE series, this cell line exhibits rapid proliferation with a doubling time of approximately 13.7 hours and demonstrates robust tumorigenic potential in immunocompromised murine hosts. Genomic profiling reveals that KYSE-150 carries the highest tumor mutation burden (70.4 mutations/Mb) among common ESCC cell lines, with prominent dysregulation in Hippo, Notch, PI3K, RTK-Ras, and Wnt signaling pathways. Additionally, the cell line exhibits up-regulated invasion-related gene expression and defective homologous recombination deficiency (HRD) signature enrichment, making it particularly relevant for studying aggressive tumor phenotypes and DNA damage response therapeutics.

In xenograft applications, KYSE-150 cells reliably form subcutaneous tumors in athymic nude mice when implanted with Matrigel support, providing a consistent and reproducible model for preclinical pharmacology studies. The model has been widely utilized to evaluate chemotherapeutic agents, targeted therapies, and combination regimens, offering valuable insights into tumor growth kinetics, treatment response, and biomarker dynamics in ESCC research.

Figure 1. The late cell apoptosis for KYSE-150 cell line. (Cui, Yuzhong, et al., 2022)

Cell Line Information: KYSE-150

The following table summarizes the essential characteristics and molecular profile of the KYSE-150 cell line:

Our Services

Alfa Cytology specializes in the development and deployment of validated KYSE-150 xenograft models for preclinical ESCC research. Our integrated service platform encompasses model establishment, in-life study management, tumor monitoring, endpoint analysis, and comprehensive data reporting, ensuring high-quality, reproducible results that support informed decision-making throughout your drug discovery and development programs.

Workflow of KYSE-150 Xenograft Model Construction

Alfa Cytology follows a standardized, quality-controlled workflow to establish KYSE-150 xenograft models, ensuring consistent tumor engraftment and reliable pharmacological readouts. Each step is executed under strict GLP-compliant conditions with comprehensive documentation and quality assurance oversight.

1. Cell Line Authentication and Preparation: KYSE-150 cells are authenticated via STR profiling and mycoplasma testing prior to expansion. Cells are cultured under standard conditions and harvested at optimal confluence for implantation.
2. Host Strain Selection and Acclimation: Female athymic nude mice (Foxn1nu) approximately 6-8 weeks of age are acclimated for at least 5 days under controlled environmental conditions with sterilized diet and water.
3. Cell Implantation: A suspension of 5.0 x 10^6 KYSE-150 cells mixed 1:1 with GFR Matrigel is injected subcutaneously into the right flank of each mouse under aseptic conditions.
4. Tumor Engraftment Monitoring: Tumor growth is assessed twice weekly using digital caliper measurements. Tumor volume is calculated using the formula: Volume = (Length x Width^2) / 2. Mice are randomized into treatment groups when tumors reach 100-200 mm^3.
5. Treatment Administration and In-Life Monitoring: Test compounds are administered according to the study protocol (PO, IP, or IV routes). Body weights and clinical signs are recorded throughout the study period to evaluate treatment tolerability.
6. Endpoint Analysis and Tissue Collection: At study termination, tumors are excised, weighed, and processed for downstream analyses including histopathology (H&E), immunohistochemistry (IHC), and biomarker profiling.
7. Data Compilation and Reporting: All data are compiled into a comprehensive study report including tumor growth curves, tumor growth inhibition (TGI) calculations, body weight changes, and statistical analysis.

Figure 2: Schematic workflow illustrating the derivation and construction of the KYSE-150 Xenograft Model at Alfa Cytology.

Case Study-KYSE-150 Xenograft Model Development

In a representative preclinical engagement, Alfa Cytology successfully established subcutaneous KYSE-150 xenografts in athymic nude mice to evaluate a novel therapeutic candidate targeting DNA damage response pathways. The study demonstrated consistent tumor engraftment with predictable growth kinetics, enabling robust pharmacodynamic assessment. Treatment arms showed dose-dependent tumor growth inhibition compared to vehicle controls, with corresponding modulation of pharmacodynamic biomarkers in excised tumor tissue. These findings illustrate the utility of the KYSE-150 model for evaluating targeted agents in ESCC and provide a foundation for subsequent translational studies. (Detailed data available upon request.)

Why Choose Alfa Cytology?

Alfa Cytology delivers scientifically rigorous, operationally efficient KYSE-150 xenograft model services designed to meet the demands of modern preclinical oncology research. Our commitment to quality, transparency, and client collaboration ensures that every study generates actionable, high-confidence data.

• Fully authenticated KYSE-150 cell lines with verified STR profiles and mycoplasma-free certification ensure model integrity from inception.
• Standardized xenograft workflows with rigorous quality control and GLP-compliant documentation guarantee reproducible, audit-ready results.
• Comprehensive in-life capabilities including tumor monitoring, body weight tracking, and clinical observation by experienced veterinary staff.
• Flexible study designs accommodating single-agent, combination, and dose-escalation protocols with customizable endpoints and biomarker analysis.
• Integrated histopathology, IHC, and molecular profiling services provide mechanistic insights beyond standard tumor volume measurements.
• Dedicated project management with transparent communication, milestone tracking, and timely delivery of comprehensive study reports.

Contact Us

Ready to advance your ESCC therapeutic pipeline with our validated KYSE-150 xenograft model? Please reach out to us today via our inquiry form or email to learn more about our KYSE-150 Xenograft Model services.

For research use only. Not intended for any clinical use.